Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 166, Issue 23, 2019, Pages 11418-11427

  Takashi, Yuichi ^a,b   Kosako, Hidetaka ^a   Sawatsubashi, Shun ^a   Kinoshita, Yuka ^b   Ito, Nobuaki ^b   Tsoumpra, Maria K ^a   Nangaku, Masaomi ^b   Abe, Masahiro ^a   Matsuhisa, Munehide ^a   Kato, Shigeaki ^c,d   Matsumoto, Toshio ^a   Fukumoto, Seiji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c IWAKI MEISEI UNIVERSITY   (Japan)

^d Jyoban Hospital   (Japan)

Author keywords

Fibroblast growth factor 23; Fibroblast growth factor receptor 1; Phosphate sensor

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATE; FIBROBLAST GROWTH FACTOR; SCLEROPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMUR; GALNT3 GENE; GENE DELETION; GENE EXPRESSION; GENE INDUCTION; GENE PRODUCT; LIGAND BINDING; MALE; MAPK SIGNALING; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCYTE; PHOSPHATE INTAKE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN SYNTHESIS; PROTEOMICS; RAT; RECEPTOR UPREGULATION; ANIMAL; GLYCOSYLATION; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; EXTRACELLULAR MATRIX PROTEINS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLAST GROWTH FACTORS; GLYCOSYLATION; MALE; MICE; MICE, INBRED ICR; OSTEOBLASTS; OSTEOCYTES; PHOSPHATES; PHOSPHORYLATION; PROTEOLYSIS; PROTEOMICS; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 85066784166     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1815166116     Document Type: Article

References (43)

1. S. Fukumoto, FGF23-FGF receptor/Klotho pathway as a new drug target for disorders of bone and mineral metabolism. Calcif. Tissue Int. 98, 334-340 (2016).
2. T. Shimada et al., Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 113, 561-568 (2004).
3. D. M. Ornitz, N. Itoh, The fibroblast growth factor signaling pathway. Wiley Interdiscip. Rev. Dev. Biol. 4, 215-266 (2015).
4. I. Urakawa et al., Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444, 770-774 (2006).
5. T. Shimada et al., FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 19, 429-435 (2004).
6. J. Q. Feng et al., Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat. Genet. 38, 1310-1315 (2006).
7. S. Liu et al., Pathogenic role of Fgf23 in Hyp mice. Am. J. Physiol. Endocrinol. Metab. 291, E38-E49 (2006).
8. V. S. Tagliabracci et al., Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc. Natl. Acad. Sci. U.S.A. 111, 5520-5525 (2014).
9. L. Song, A. D. Linstedt, Inhibitor of ppGalNAc-T3-mediated O-glycosylation blocks cancer cell invasiveness and lowers FGF23 levels. eLife 6, e24051 (2017).
10. Y. Frishberg et al., Hyperostosis-hyperphosphatemia syndrome: A congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J. Bone Miner. Res. 22, 235-242 (2007).
11. E. P. Bennett et al., Control of mucin-type O-glycosylation: A classification of the polypeptide GalNAc-transferase gene family. Glycobiology 22, 736-756 (2012).
12. M. Yamazaki et al., Both FGF23 and extracellular phosphate activate Raf/MEK/ERK pathway via FGF receptors in HEK293 cells. J. Cell. Biochem. 111, 1210-1221 (2010).
13. M. Kimata et al., Signaling of extracellular inorganic phosphate up-regulates cyclin D1 expression in proliferating chondrocytes via the Na+/Pi cotransporter Pit-1 and Raf/MEK/ERK pathway. Bone 47, 938-947 (2010).
14. M. M. McKay, D. K. Morrison, Integrating signals from RTKs to ERK/MAPK. Oncogene 26, 3113-3121 (2007).
15. J. Nishino et al., Extracellular phosphate induces the expression of dentin matrix protein 1 through the FGF receptor in osteoblasts. J. Cell. Biochem. 118, 1151-1163 (2017).
16. C. M. Furdui, E. D. Lew, J. Schlessinger, K. S. Anderson, Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. Mol. Cell 21, 711-717 (2006).
17. E. D. Lew, C. M. Furdui, K. S. Anderson, J. Schlessinger, The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations. Sci. Signal. 2, ra6 (2009).
18. R. Goetz, M. Mohammadi, Exploring mechanisms of FGF signalling through the lens of structural biology. Nat. Rev. Mol. Cell Biol. 14, 166-180 (2013).
19. N. Gotoh, Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins. Cancer Sci. 99, 1319-1325 (2008).
20. M. Zhang et al., Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J. Biol. Chem. 277, 44005-44012 (2002).
21. R. Trokovic et al., FGFR1 is independently required in both developing mid- and hindbrain for sustained response to isthmic signals. EMBO J. 22, 1811-1823 (2003).
22. K. E. White et al., Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am. J. Hum. Genet. 76, 361-367 (2005).
23. J. Silver, T. Naveh-Many, Phosphate and the parathyroid. Kidney Int. 75, 898-905 (2009).
24. G. Papaioannou et al., Raf kinases are essential for phosphate induction of ERK1/ 2 phosphorylation in hypertrophic chondrocytes and normal endochondral bone development. J. Biol. Chem. 292, 3164-3171 (2017).
25. S. Jono et al., Phosphate regulation of vascular smooth muscle cell calcification. Circ. Res. 87, E10-E17 (2000).
26. H. Saito et al., Circulating FGF-23 is regulated by 1α, 25-dihydroxyvitamin D3 and phosphorus in vivo. J. Biol. Chem. 280, 2543-2549 (2005).
27. Y. Fan et al., Parathyroid hormone 1 receptor is essential to induce FGF23 production and maintain systemic mineral ion homeostasis. FASEB J. 30, 428-440 (2016).
28. M. Hori, Y. Kinoshita, M. Taguchi, S. Fukumoto, Phosphate enhances Fgf23 expression through reactive oxygen species in UMR-106 cells. J. Bone Miner. Metab. 34, 132-139 (2016).
29. M. Nomoto et al., Structural basis for the regulation of UDP-N-acetyl-alpha-Dgalactosamine: Polypeptide N-acetylgalactosaminyl transferase-3 gene expression in adenocarcinoma cells. Cancer Res. 59, 6214-6222 (1999).
30. S. Sarabipour, K. Hristova, Mechanism of FGF receptor dimerization and activation. Nat. Commun. 7, 10262 (2016).
31. L. Comps-Agrar, D. R. Dunshee, D. L. Eaton, J. Sonoda, Unliganded fibroblast growth factor receptor 1 forms density-independent dimers. J. Biol. Chem. 290, 24166-24177 (2015).
32. C. C. Lin et al., Inhibition of basal FGF receptor signaling by dimeric Grb2. Cell 149, 1514-1524 (2012).
33. E. V. Bocharov et al., Structure of FGFR3 transmembrane domain dimer: Implications for signaling and human pathologies. Structure 21, 2087-2093 (2013).
34. N. Bon et al., Phosphate-dependent FGF23 secretion is modulated by PiT2/Slc20a2. Mol. Metab. 11, 197-204 (2018).
35. N. Bon et al., Phosphate (Pi)-regulated heterodimerization of the high-affinity sodium-dependent Pi transporters PiT1/Slc20a1 and PiT2/Slc20a2 underlies extracellular Pi sensing independently of Pi uptake. J. Biol. Chem. 293, 2102-2114 (2018).
36. O. Topaz et al., Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat. Genet. 36, 579-581 (2004).
37. V. Guagnano et al., Discovery of 3-(2, 6-dichloro-3, 5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J. Med. Chem. 54, 7066-7083 (2011).
38. Y. Yamazaki et al., Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J. Clin. Endocrinol. Metab. 87, 4957-4960 (2002).
39. E. Ishikawa et al., Protein kinase D regulates positive selection of CD4+ thymocytes through phosphorylation of SHP-1. Nat. Commun. 7, 12756 (2016).
40. Y. Abe, M. Nagano, A. Tada, J. Adachi, T. Tomonaga, Deep phosphotyrosine proteomics by optimization of phosphotyrosine enrichment and MS/MS parameters. J. Proteome Res. 16, 1077-1086 (2017).
41. K. Motani, H. Kosako, Activation of stimulator of interferon genes (STING) induces ADAM17-mediated shedding of the immune semaphorin SEMA4D. J. Biol. Chem. 293, 7717-7726 (2018).
42. S. Okuda et al., jPOSTrepo: An international standard data repository for proteomes. Nucleic Acids Res. 45, D1107-D1111 (2017).
43. J. R. Graham, M. C. Hendershott, J. Terragni, G. M. Cooper, mRNA degradation plays a significant role in the program of gene expression regulated by phosphatidylinositol 3-kinase signaling. Mol. Cell. Biol. 30, 5295-5305 (2010).